Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2024 (Event Date); March 12, 2024 (Closing Date)
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement for a private placement offering of equity and warrants to institutional and accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10.1 million (before placement agent fees and expenses).
- Offering Price: $4.55 per unit (comprising one share of Common Stock or one Pre-Funded Warrant plus accompanying Series H-1 and H-2 Warrants).
- Securities Issued:
- 675,183 shares of Common Stock.
- 1,548,150 Series I Pre-Funded Warrants (exercise price: $0.01).
- 2,223,333 Series H-1 Warrants (exercise price: $4.55; term: 18 months post-registration).
- 2,223,333 Series H-2 Warrants (exercise price: $4.55; term: 5 years, reducible to 20 days upon 510k clearance).
- Placement Agent Fees:
- Cash fee: 8.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Warrants: 5% of aggregate Shares and Pre-Funded Warrants sold (exercise price: 125% of offering price).
- Contingent fee: 9.0% of gross proceeds from cash exercise of H-1 and H-2 Warrants.
- Expense reimbursement: Up to $145,000.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the Company's operations.
Material Changes and Agreements
The primary material change is the execution of a private placement offering closed on March 12, 2024. Key contractual obligations include:
- Registration Rights: The Company agreed to file a resale registration statement by March 18, 2024, and use best efforts to have it declared effective by April 22, 2024.
- Warrant Terms: Series H-2 Warrants contain a specific acceleration clause reducing the exercise term to 20 calendar days if the Company announces 510k clearance by the FDA for its Intelligent Fingerprinting Drug Screening System.
Outlook, Risks, and Contingencies
- Regulatory Contingency: The exercise term of Series H-2 Warrants is contingent upon the FDA granting 510k clearance for the Company's drug screening system.
- Dilution Risk: The offering includes significant warrant coverage (Pre-Funded, Series H-1, Series H-2, and Placement Agent Warrants) which may result in substantial dilution upon exercise.
- Market Risk: The securities were sold under Section 4(a)(2) and Rule 506 exemptions; resale is subject to the effectiveness of the registration statement.
Investor Verification Checklist
- Verify the effectiveness date of the Resale Registration Statement (target: April 22, 2024).
- Monitor FDA announcements regarding 510k clearance for the Intelligent Fingerprinting Drug Screening System to assess Series H-2 Warrant exercise windows.
- Review the Company's latest 10-K or 10-Q for current cash balances and burn rate to contextualize the $10.1 million gross proceeds.
- Confirm the total number of shares outstanding post-offering to calculate immediate dilution impact.